99% Purity Ribociclib Powder Pharmaceutical Intermediate Ribociclib Succinate Powder Ribociclib

• Powder: Yes
• Customized: Customized
• Certification: GMP, HSE, ISO 9001, USP, BP
• Suitable for: Elderly, Children, Adult
• State: Powder
• Purity: >99%
• Model NO.: Dsung-Ribociclib
• Product Name: Ribociclib
• Name: Ribociclib Powder
• Appearance: White Powder
• Grade: Pharmaceutical Grade
• Assay: HPLC 99%
• Application: Anticancer
• Specific: COA
• Test Method: HPLC
• Shelf Life: 2 Years
• CAS No.: 1211441-98-3
• Mf: C23h30n8o
• MW: 434.548
• Density: 1.39+-0.1 g/cm3(Predicted)
• Boiling Point: 730.8+-70.0 C(Predicted)
• Refractive Index: 1.723
• Transport Package: Negotiable
• Specification: 99%
• Trademark: D-Sung
• Origin: Shaanxi
• Production Capacity: 500 Kg/Month

Product Description

99% Purity Ribociclib Powder Pharmaceutical Intermediate Ribociclib Succinate Powder Ribociclib

 

Product Description

Product Details

Product Name	Ribociclib
CAS No.	1211441-98-3
MF	C23H30N8O
MW	434.548
Appearance and shape	White powder

Ribociclib is an orally available cyclin-dependent kinase (CDK) inhibitor targeting cyclin D1/CDK4 and cyclin D3/CDK6 cell cycle pathway, with potential antineoplastic activity. Ribociclib specifically inhibits CDK4 and 6, thereby inhibiting retinoblastoma (Rb) protein phosphorylation. Ribociclib does not currently have Marketing Authorisation in the EU for any indication. Ribociclib is in phase II studies for breast cancer.

Application & Function

Ribociclib is a selective cyclin-dependent kinase inhibitor, a class of drugs that help slow the progression of cancer by inhibiting two proteins called cyclin-dependent kinase 4 and 6 (CDK4/6).   These proteins, when over-activated, can enable cancer cells to grow and divide too quickly.   Targeting CDK4/6 with enhanced precision may play a role in ensuring that cancer cells do not continue to replicate uncontrollably.
It is indicated for the treatment of women with hormone receptor (HR)-positive, negative locally advanced or metastatic breast cancer in combination with an aromatase inhibitor as initial endocrine-based therapy, or in women who have received prior endocrine therapy.   In pre- or perimenopausal women, the endocrine therapy should be combined with a luteinising hormone-releasing hormone (LHRH) agonist.

Specification